Search results
Results From The WOW.Com Content Network
Biogen stock is a component of several stock indices such as the S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. [11] In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million. [12]
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
List of largest biomedical companies by market capitalization. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) with current market capitalization of at least US$10 billion, ranked by their market capitalization. It does not include biotechnology companies that ...
Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until ...
Biogen said it will pay Reata $172.50 per share in cash, which represents a 58.9% premium to the stock's last closing price. Including debt, the deal values Reata at roughly $7.3 billion.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates ...
Let's see what those numbers can tell us about how expensive or cheap Biogen Idec (NAS: BIIB) might be. The current price multiples First, we'll look at most investors' favorite metric: the P/E ratio.
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [5]